UX053 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 257 | 肝型糖原病 | 3 |
257. 肝型糖原病
臨床試験数 : 14 / 薬物数 : 27 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 8
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-000903-19-IT (EUCTR) | 14/12/2021 | 24/05/2021 | A first-in-human study of UX053 in Patients with Glycogen Storage Disease type III (GSD III) | A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind, Placebo-controlled) of UX053 in Patients with GSD III - UX053-CL101 | Glycogen Storage Disease Type III (GSD III) MedDRA version: 20.1;Level: PT;Classification code 10053250;Term: Glycogen storage disease type III;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: mRNA che codifica l’enzima umano deramificante del glicogeno formulato in una nanopaticella lipidica Product Code: [UX053] Product Name: dexamethasone (or equivalent) Product Code: [-] | ULTRAGENYX PHARMACEUTICAL INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 1;Phase 2 | France;United States;Canada;Spain;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2021-000903-19-ES (EUCTR) | 26/11/2021 | 20/07/2021 | A first-in-human study of UX053 in Patients with Glycogen Storage Disease type III (GSD III) | A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind, Placebo-controlled) of UX053 in Patients with GSD III | Glycogen Storage Disease Type III (GSD III) MedDRA version: 20.1;Level: PT;Classification code 10053250;Term: Glycogen storage disease type III;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: mRNA encoding the human glycogen debranching enzyme formulated in a lipid nanoparticle delivery Product Code: UX053 INN or Proposed INN: Not yet available Other descriptive name: mRNA encoding the human glycogen debranching enzyme | Ultragenyx Pharmaceutical Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 1;Phase 2 | France;United States;Canada;Spain;Germany;United Kingdom;Italy | ||
| 3 | NCT04990388 (ClinicalTrials.gov) | October 18, 2021 | 26/7/2021 | Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) | A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III | Glycogen Storage Disease Type III | Biological: UX053;Other: Placebo;Drug: Antipyretic;Drug: H2 Blocker;Drug: H1 Blocker | Ultragenyx Pharmaceutical Inc | NULL | Active, not recruiting | 18 Years | N/A | All | 8 | Phase 1/Phase 2 | United States;Canada;France;Italy;Spain;United Kingdom |